SMALL cell lung cancerOVERALL survivalPREVENTIVE medicineDOXORUBICINIntroduction. Small-cell lung cancer (SCLC) is an aggressive disease. Despite the first-line (1L) chemotherapy, almost all patients need the second-line (2L) treatment within a year. However, there is no general agre...
参考文献: [1]Shi Y et al., Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG), ELCC 2022, Oral Presentation, Abstract...
Researchers studying a large set ofsmall cell lung cancer (SCLC)tumor samples have identified four SCLC subtypes, and they propose that matching baseline tumor subtypes to SCLC therapy may enhance the depth and duration of response. Carl M. Gay, MD, PhD, of University of Texas MD Anderson Ca...
Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to compare costs and effectiveness in patients who received third-line erlotinib to those in a historical patient cohort that...
An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Araujo, A,Parente, B,SottoMayor, R,... - 《Revista Portuguesa De Pneumologia》 - 2008 - 被引量: 35 Rigosertib v...
Objective:To observe the efficacy of erlotinib plus best supportive care in treatment of patients with advanced non-small cell lung cancer (NSCLC).Methods:Twenty-one patients with advanced NSCLC( Ⅲb /Ⅳ stage) were recruited in this study.They had recurrence after receiving at least one or two...
11. Reck M, Ciuleanu TE, Cobo Dols M, et al. Nivolumab (NIVO) + ipilimumab(IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.J Clin Oncol. 20...
5.Wang, et al. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control...
7.West H,McCleod M,Hussein M,et al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer(IMpower130):a multicentre,randomised,open-label,phase 3 trial[J].Lancet On...
A letter to the editor is presented in response to the article related to the approach used for the second-line treatment of non-small-cell lung cancer with wild-type epidermal growth factor receptor (EGFR) by Ibrahim Elghissassi in the previous issue.Current OncologyKim Anh ...